| ¿µ¹® | toxicity | ÇÑ±Û | µ¶¼º |
|---|---|---|---|
| ¼³¸í | »ýü¿¡ ÀÖ¾î ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº ¾à¹° ÀÛ¿ëÀ» ¸»ÇÑ´Ù. ¾à¹°À» °ú·®À¸·Î »ç¿ëÇϸé Áßµ¶À» ÀÏÀ¸Å°¸ç, ½ÉÇÑ °æ¿ì¿¡´Â Á×À½¿¡ À̸£´Âµ¥ ÀÌ´Â ¾à¹°ÀÇ ±Þ¼º µ¶¼ºÀÌ´Ù. ¸¸¼º µ¶¼ºÀº ¼Ò·®À» Àå±â°£ ¹Ýº¹ ¼·ÃëÇÏ¿´À» ¶§ÀÇ µ¶¼ºÀÌ´Ù. °£, ÄáÆÏ µî ¿©·¯ Àå±â¿Í Á¶Á÷¿¡ ´ëÇÑ µ¶¼º ¿Ü¿¡, ±âÇüÀ¯¹ß¼º, ¹ß¾Ï¼º µîµµ ¾à¹°µ¶¼ºÀÌ´Ù. ¾à¹°µ¶¼ºÀÇ °¾àÀº ±Þ¼º µ¶¼º°Ë»ç(LD50), ¸¸¼º µ¶¼º°Ë»ç, ±âÇüÀ¯¹ß°Ë»ç, ¹ß¾Ï°Ë»ç, ¹ø½Ä°Ë»ç ±âŸ ¿©·¯ µ¿¹°°Ë»ç¿¡ ÀÇÇØ ÆÇÁ¤µÈ´Ù. |
||
| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | drug | ÇÑ±Û | ¾à, ¾à¹°, ¾àÁ¦ |
|---|---|---|---|
| ¼³¸í | 1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â ÈÇÕ¹°. ¾à¸®Çп¡¼´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÈÇй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, üÁß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í ÀÖ´Â ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| DA | dark adaptation; dark agouti [rat]; daunomycin; degenerative arthritis; delayed action; Dental Assis... |
| EUROTOX | European Committee on Chronic Toxicity Hazards |
| I&T | intolerance and toxicity |
| TCLP | Toxicity Characteristic Leachate Procedure [EPA battery test] |
| CTC | Common Toxicity Criteria |
|---|---|
| DLT | Dose limiting toxicity |
| RRT | Regimen related toxicity |
| TCLP | Toxicity Characteristic Leaching Procedure |
| TIE | Toxicity Identification Evaluation |
| drug toxicity | The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug. (27 Sep 1997) |
|---|
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
|---|---|
| acute toxicity | <pharmacology> Illness resulting from a single dose or exposure to a toxic substance. Compare: chronic toxicity. (06 May 1997) |
| chronic toxicity | <pharmacology> Illness caused by repeated or long-term exposure to low doses of a toxic substance. Compare: acute toxicity. (09 Oct 1997) |
| digitalis toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| digoxin toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| oxygen toxicity | A body disturbance resulting from breathing high partial pressures of oxygen; characterised by visual and hearing abnormalities, unusual fatigue while breathing, muscular twitching, anxiety, confusion, incoordination, and convulsions; although the mechanism for development of the condition is obscure, a disruption of enzymatic activity is likely, perhaps as a result of free radical formation. Synonym: oxygen poisoning. (05 Mar 2000) |
| toxicity | The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. (18 Nov 1997) |
| toxicity test | <investigation> Controlled laboratory test to determine the toxicity of a chemical to an organism in terms of specific chemical concentrations. An acute toxicity test establishes the concentration required to kill a predetermined proportion of test organisms within a relatively short period of time, typically 4 days or less. A chronic toxicity test reveals the effects of a sublethal concentration applied throughout all or part of the life cycle. (12 Jan 1998) |
| toxicity tests | Tests that determine the toxicity of a substance. These include tests of clinical drugs, foods, environmental pollutants, etc. (12 Dec 1998) |
| ep toxicity | A test defined by the federal Environmental Protection Agency to check a substance for the presence of arsenic, barium, cadmium, chromium, lead, mercury, selenium, or silver. 40 CFR 261.24 defines the concentrations constituting hazardous waste and the test procedure. (05 Dec 1998) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
Synonyms : Drug Safety, Toxicity, Drug, Drug Toxicities, Safety, Drug, Toxicities, Drug
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|